These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32503668)

  • 41. Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.
    Nakamura H; Kinjo T; Arakaki W; Miyagi K; Tateyama M; Fujita J
    Crit Care; 2020 Aug; 24(1):484. PubMed ID: 32753065
    [No Abstract]   [Full Text] [Related]  

  • 42. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19.
    Shah A; Frost JN; Aaron L; Donovan K; Drakesmith H;
    Crit Care; 2020 Jun; 24(1):320. PubMed ID: 32517773
    [No Abstract]   [Full Text] [Related]  

  • 43. NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
    Stiel L; Rabouel Y; Debliquis A; Pointurier V; Mootien J; Kuteifan K
    Dis Markers; 2021; 2021():4361844. PubMed ID: 34840629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A high blood endocan profile during COVID-19 distinguishes moderate from severe acute respiratory distress syndrome.
    Pascreau T; Tcherakian C; Zuber B; Farfour E; Vasse M; Lassalle P
    Crit Care; 2021 May; 25(1):166. PubMed ID: 33957951
    [No Abstract]   [Full Text] [Related]  

  • 45. Distinct temporal characteristics of circulating alveolar epithelial and endothelial injury markers in ARDS with COVID-19.
    Tojo K; Yamamoto N; Mihara T; Abe M; Goto T
    Crit Care; 2021 May; 25(1):169. PubMed ID: 34001181
    [No Abstract]   [Full Text] [Related]  

  • 46. Focus on ventilation and ARDS: recent insights.
    De Jong A; Jaber S; Ferguson ND
    Intensive Care Med; 2019 Nov; 45(11):1635-1638. PubMed ID: 31620833
    [No Abstract]   [Full Text] [Related]  

  • 47. Focus on ARDS.
    Neto AS; Dessap AM; Papazian L
    Intensive Care Med; 2017 Oct; 43(10):1495-1497. PubMed ID: 28779224
    [No Abstract]   [Full Text] [Related]  

  • 48. Neutrophil-Lymphocyte Ratio as a Novel Biomarker of Prognosis in Patients With Heart Failure.
    Mi W; Li T
    Angiology; 2024 Sep; 75(8):798-799. PubMed ID: 38051403
    [No Abstract]   [Full Text] [Related]  

  • 49. Linking genetics to ARDS pathogenesis: the role of the platelet.
    Reilly JP; Christie JD
    Chest; 2015 Mar; 147(3):585-586. PubMed ID: 25732436
    [No Abstract]   [Full Text] [Related]  

  • 50. Cholestenoic acid is a prognostic biomarker in acute respiratory distress syndrome.
    Madenspacher JH; Stapleton RD; Suratt BT; Dixon AE; Lih FB; Lowe JM; Mould KJ; Janssen WJ; Morrell ED; Wurfel MM; Garantziotis S; Tomer KB; Fessler MB
    J Allergy Clin Immunol; 2019 Jan; 143(1):440-442.e8. PubMed ID: 30296525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.
    Ye W; Chen G; Li X; Lan X; Ji C; Hou M; Zhang D; Zeng G; Wang Y; Xu C; Lu W; Cui R; Cai Y; Huang H; Yang L
    Respir Res; 2020 Jul; 21(1):169. PubMed ID: 32620118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients.
    Tatum D; Taghavi S; Houghton A; Stover J; Toraih E; Duchesne J
    Shock; 2020 Nov; 54(5):652-658. PubMed ID: 32554992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy.
    Ciceri F; Castagna A; Rovere-Querini P; De Cobelli F; Ruggeri A; Galli L; Conte C; De Lorenzo R; Poli A; Ambrosio A; Signorelli C; Bossi E; Fazio M; Tresoldi C; Colombo S; Monti G; Fominskiy E; Franchini S; Spessot M; Martinenghi C; Carlucci M; Beretta L; Scandroglio AM; Clementi M; Locatelli M; Tresoldi M; Scarpellini P; Martino G; Bosi E; Dagna L; Lazzarin A; Landoni G; Zangrillo A
    Clin Immunol; 2020 Aug; 217():108509. PubMed ID: 32535188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale Use of Neutrophil-to-lymphocyte ratio for early diagnosis and stratification of COVID-19.
    Zahorec R; Hulin I; Zahorec P
    Bratisl Lek Listy; 2020; 121(7):466-470. PubMed ID: 32989997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19.
    Kong M; Zhang H; Cao X; Mao X; Lu Z
    Epidemiol Infect; 2020 Jul; 148():e139. PubMed ID: 32641174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study.
    Coppo A; Bellani G; Winterton D; Di Pierro M; Soria A; Faverio P; Cairo M; Mori S; Messinesi G; Contro E; Bonfanti P; Benini A; Valsecchi MG; Antolini L; Foti G
    Lancet Respir Med; 2020 Aug; 8(8):765-774. PubMed ID: 32569585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19.
    Maquet J; Lafaurie M; Sommet A; Moulis G
    Br J Haematol; 2020 Sep; 190(5):e276-e279. PubMed ID: 32557535
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.
    Deftereos SG; Giannopoulos G; Vrachatis DA; Siasos GD; Giotaki SG; Gargalianos P; Metallidis S; Sianos G; Baltagiannis S; Panagopoulos P; Dolianitis K; Randou E; Syrigos K; Kotanidou A; Koulouris NG; Milionis H; Sipsas N; Gogos C; Tsoukalas G; Olympios CD; Tsagalou E; Migdalis I; Gerakari S; Angelidis C; Alexopoulos D; Davlouros P; Hahalis G; Kanonidis I; Katritsis D; Kolettis T; Manolis AS; Michalis L; Naka KK; Pyrgakis VN; Toutouzas KP; Triposkiadis F; Tsioufis K; Vavouranakis E; Martinèz-Dolz L; Reimers B; Stefanini GG; Cleman M; Goudevenos J; Tsiodras S; Tousoulis D; Iliodromitis E; Mehran R; Dangas G; Stefanadis C;
    JAMA Netw Open; 2020 Jun; 3(6):e2013136. PubMed ID: 32579195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-α2b Treatment for COVID-19.
    Zhou Q; Chen V; Shannon CP; Wei XS; Xiang X; Wang X; Wang ZH; Tebbutt SJ; Kollmann TR; Fish EN
    Front Immunol; 2020; 11():1061. PubMed ID: 32574262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.